10 MARKET La-5 and B. animalis subsp. lac- Ingredion has also carried out tis BB-12 in diabetic subjects. L. studies with its new prebio- acidophilus NCFM also allows tic fibre, Weightain™ Satiety. insulin sensitivity preservation in the persons with type 2 diabetes. It has recently clinically demons- trated its effectiveness in reducing A next-generation probiotic blood sugar and insulin response created from a bacterium in the to meals, after having proven its microbiota, Akkermansia muci- effect on satiety (50 to 100 calo- niphila, is currently being tested ries reduction per day). Solactis in humans. It could be highly ef- has also demonstrated the be- fective in fighting diabetes and nefits of its galactofructose and obesity. In the private research has received a positive opinion sector, Caelus Health has recent- from EFSA for a claim on gly- ly identified and patented Eubac- caemic response management. terium hallii, which has proven its capacity to reduce insulin re- sistance in preclinical studies. Its CP-001 strain is currently in phase I clinical study. Very inte- rested in this probiotic, Chr.Hansen has started a collaboration with Caelus Health targeting diabetes. Dupont™ Danisco’s strain Bifido- bacterium Animalis Subsp. Lactis 420, with benefits in weight loss and glucose tolerance in obese and diabetic mice, demonstrated in 2016 in a clinical trial conducted in 225 overweight and obese vo- lunteers (1010 CFU/d for 6 mon- ths) that it could lead to appetite, body fat and waist circumference reduction. The effect is reinforced by the presence of Litesse® fiber.